Hypertriglyceridemia in patients with metastatic breast cancer and treatment with capecitabine

Journal of Chemotherapy

Volumn 25, Issue 3, 2013, Pages 176-180

  Geva, Shahar ^a   Lazarev, Irena ^a   Geffen, David Barry ^a   Ariad, Samuel ^a  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

Breast cancer; Capecitabine; Diabetes mellitus; Hypertriglyceridemia; Lapatinib

Indexed keywords

CAPECITABINE; LAPATINIB; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; BODY MASS; BREAST METASTASIS; DIABETES MELLITUS; DISEASE ASSOCIATION; DYSLIPIDEMIA; FEMALE; HUMAN; HYPERTRIGLYCERIDEMIA; MAJOR CLINICAL STUDY; RETROSPECTIVE STUDY; RISK FACTOR;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DEOXYCYTIDINE; DIABETES MELLITUS; DYSLIPIDEMIAS; FEMALE; FLUOROURACIL; HUMANS; HYPERTRIGLYCERIDEMIA; ISRAEL; MIDDLE AGED; MULTIVARIATE ANALYSIS; QUINAZOLINES; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 84878169935     PISSN: 1120009X     EISSN: 19739478     Source Type: Journal    
DOI: 10.1179/1973947813Y.0000000072     Document Type: Article

References (17)

1. Jim Yeung S, Cua Chiu A, Vassilopoulou-Sellin, Gagel RF. The endocrine effects of nonhormonal antineoplastic therapy. Endocr Rev. 1998;19(2):144-72.
2. Graessle D, Bonacini M, Chen S. Alpha-interferon and reversible hypertriglyceridemia. Ann Intern Med. 1993;118(4):316-7.
3. Brattström C, Wilczek HE, Tydén G, Böttiger Y, Säwe J, Groth CG. Hypertriglyceridemia in renal transplant recipients treated with sirolimus. Transplant Proc. 1998;30(9):3950-1.
4. Ramlau R, Zatloukal P, Jassem J, Schwarzenberger P, Orlov SV, Gottfried M, et al. Randomized phase 3 trial comparing bexarotene (L1069-49)/cisplatin/vinorelbine with cisplatin/vinorelbine in chemotherapy-naïve patients with advanced or metastatic non-smallcell lung cancer: Spirit 1. J Clin Oncol. 2008;26(11):1886-92.
5. Kurt M, Babaoglu MO, Yasar U, Shorbagi A, Guler N. Capecitabine-induced severe hypertriglyceridemia: report of two cases. Ann Pharmacother. 2006;40(2):328-31.
6. Koutras AK, Habeos IG, Vagenakis AG, Kalofonos HP. Capecitabine-induced hypertriglyceridemia: a report of two cases. Anticancer Res. 2006;26(3B):2249-51.
7. Bar Sela G, Haim N. Uncontrolled hypertriglyceridemia induced by capecitabine: case report and review of the literature. Cancer Chemother Pharmacol. 2009;63(5):779-82.
8. Garg R, Angus E, Fincher S. Capecitabine-induced severe hypertriglyceridemia and diabetes: a case report and review of the literature. Diabetic Med. 2009;26(12):1306-10.
9. Pollinder-Bos HA, Kok EE, van de Wiel A, Spiering W, Wielders JPM, Bloemendal HJ. Severe hypertriglyceridemia associated with the use of capecitabine. Neth J Med. 2012;70(2):104.
10. Duman BB, Paydas S, Tetiker T, Gunaldi M, Afsar CU, Erçolak V, et al. Capecitabine-induced hypertriglyceridemia: two cases. Pharmacology. 2012;90(3-4):212-5.
11. Michie CO, Sakala M, Rivans I, Strachan MW, Clive S. The frequency and severity of capecitabine-induced hypertriglyceridemia in routine clinical practice: a prospective study. Br J Cancer. 2010;103(5):617-21.
12. Loudet AM, Dousset N, Carton M, Douste-Blazy L. Effects of an antimitotic agent (cyclophosphamide) on plasma lipoproteins. Biochem Pharmacol. 1984;33(19):2961-5.
13. Stathopoulus GP, Koutantos J, Lazaki H, Rigatos SK, Stathopoulos J, Deliconstantinos G. Capecitabine (Xeloda) as monotherapy in advanced breast and colorectal cancer. Anticancer Res. 2007;27(3B):1654-6.
14. Ferretti G, Felici A, Papaldo P, Fabi A, Cognetti F. HER2/neu role in breast cancer: from a prognostic foe to a predictive friend. Curr Opin Obstet Gynecol. 2007;19(1):56-62.
15. Demirci U, Buyukberber S, Yilmaz G, Kerem M, Coskun U, Uner A, et al. Hepatotoxicity associated with lapatinib in an experimental rat model. Eur J Cancer. 2012;48(2):279-85.
16. Available from: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=63319b01-cad6-4d0a-c39b-938fa951a808
17. Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006;355(26):2733-43.